Claims

1. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of diabetes mellitus type 2, wherein the pharmaceutical composition comprises
   (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and
   (b) insulin glargine or/and a pharmaceutically acceptable salt thereof,
   wherein the compound (b) is present in a concentration of 100 U/ml, and compound (a) is present in a concentration of 50 µg/ml, and
   wherein the pharmaceutical composition is to be administrated as add-on to the treatment with metformin or/and a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein a dose of 0.25 to 1.5 U/kg body weight insulin glargine is to be administered, or a dose of 0.05 to 0.5 µg/kg body weight lixisenatide is to be administered.

3. The use of claim 1 or 2, wherein diabetes mellitus type 2 is not adequately controlled with metformin alone.

4. The use of any one of the claims 1 to 3, wherein the subject to be treated has a HbA1c value of at least 7 %, at least 8 % or at least 9% at the onset of treatment with the composition.

5. The use of any one of the claims 1 to 4, wherein the subject to be treated has
   (a) a fasting plasma glucose concentration of at least 7 mmol/L, at least 8 mmol/L, at least 9 mmol/L, at least 10 mmol/L, or at least 11 mmol/L at the onset of treatment with the composition,
   (b) a self-monitored plasma glucose concentration of at least 8 mmol/L, at least 9 mmol/L, at least 10 mmol/L, or at least 11 mmol/L at the onset of treatment with the composition,
   (c) a 2-hour postprandial plasma glucose of at least 12 mmol/L, at least

13 mmol/L, at least 14 mmol/L, at least 15 mmol/L, at least 16 mmol/L, or at least 17 mmol/L at the onset of treatment with the composition, or/and

(d) a 2-hour postprandial plasma glucose excursion of at least 5 mmol/L, at least 5.5 mmol/L, at least 6 mmol/L, at least 6.5 mmol/L, or at least 7 mmol/L at the onset of treatment with the composition.

6. The use of any one of the claims 1 to 5, wherein the patient to be treated does not receive a GLP-1 receptor agonist or/and an insulin.

7. The use of any one of the claims 1 to 6, wherein the composition is to be administered parenterally.

8. The use of any one of the claims 1 to 7, wherein the subject to be treated is at least 50 years old.

9. The use of any one of the claims 1 to 8, wherein the subject to be treated has a body mass index of at least 30 kg/m^2, at least 31 kg/m^2, at least 32 kg/m^2 or at least 33 kg/m^2.

10. The use of claim 1, with the proviso that the composition is not an on-site mixed composition.

11. The use of claim 1 or 10, which is provided within a container.